CD274 and non-small cell lung carcinoma: In conclusion, our study suggested that the addition of chemotherapy to PD-1 inhibitors did not improve clinical outcomes compared to monotherapy with PD-1/PD-L1 inhibitors in second-line or later treatment settings for patients with advanced NSCLC.